List of Diagnostics Companies in California - 202

Abaxis develops and commercializes medical device and innovative technology and services that support best medical practices, enabling practitioners to respond to the health needs of their patients, while operating point of care, onsite diagnostics for human and animal health.Abaxis is now part of Zoetis.

Since its inception in 2013, AccuraGen has pioneered the development of liquid biopsy technology to facilitate more personalized cancer treatment. Our international team of scientists brings together the best of industry with the best of academia. We currently operate from two locations: Menlo Park, California and Shanghai, China.

ACON Laboratories is an international diagnostic and medical device company with our corporate headquarters in San Diego, California USA. For more than 15 years, ACON has led the way in making high quality diagnostic and medical devices more affordable to people all around the world. The ACON name is well known in over 130 countries. Headquartered in San Diego, California, the US office is the center of strategic management, administration, business development, innovative research and development. Our state of the art manufacturing facility is ISO 13485:2003 certified, FDA registered and has been inspected by US FDA. Our current product lines include Diabetes Care, Clinical Chemistry (including Urinalysis and Point of Care Tests) and Immunoassay EIA/ELISA. We also have a number of new products in the pipeline for introduction in the future.

Acutus Medical is a dynamic arrhythmia care company focused on developing distinct, innovative technologies that provide physicians and patients with improved results. AcQMap, AcQRef and AcQGuide devices are CE Marked and FDA cleared. Please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions and potential adverse events.

AdvanBio Inc., www.Advabio.com, a subsidiary of Autobio Diagnostics in the U.S is a fast-growing biotechnological company based in Irvine, CA. Established in 2021. We specialize in providing cutting-edge IVD Quality Control products & Reagents designed for a diverse range of analytes. In addition, we are committed to providing global partners with high-performance IVD Critical Raw Materials and services such as: • FDA Submission • Assay Development • Product Sales • New Technology/Biomarker Development We are committed to the advancement of medical laboratory technology and dedicated to the promotion of human health. We empower medical providers in making pivotal biomarker & diagnostic decisions with our portfolio of innovative technologies. #Advanbio#ADLM

Over the past decade, Advanced Brain Monitoring has developed and implemented mobile, user-friendly platforms for acquiring, integrating, analyzing and reporting multi-sensor data in real-world applications. Our strong and growing technical team includes PhD- and masters-level hardware engineers, biostatisticians, software engineers and experts in signal processing, experimental design and clinical trials. ABM seeks to build on existing collaborations within the academic community and develop strategic partnerships across industry with like-minded professionals.

Aegea Biotechnologies, Inc. is a technology company that is developing a series of reagents, research kits and in-vitro diagnostic (IVD) products for molecular analysis based on novel, patented and proprietary nucleic acid chemistries and methodologies.

Agena Bioscience® empowers research laboratories worldwide to deliver scalable targeted genomic data. Our advanced platforms deliver timely molecular insights in the areas of mutation profiling, liquid biopsy, pharmacogenetics, and more. Agena offers the MassARRAY® System, an open platform that provides researchers with insights through a highly multiplexed solution. Headquartered in San Diego, with offices located around the world, Agena Bioscience fosters a highly collaborative culture for both our customers and employees, encouraging diversity, creativity, and most importantly, innovation.

Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing patients with early stage breast cancer and their physicians the information they need to make the best decisions for the full treatment journey. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient. MammaPrint®, the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint®, the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings. Agendia develops evidence-based novel genomic tests and forges partnerships with groundbreaking companies to develop next-generation digital treatment tools. The ongoing research builds an arsenal of data that improve patient outcomes and support the evolving clinical needs of patients with breast cancer and their physicians every step of the way, from initial diagnosis to cancer-free. Agendia’s assays can be ordered on core biopsies or surgical specimens to inform pre- and post-operative treatment decisions. For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com. For view our social media policies, please visit https://agendia.com/legal-compliance/

Ainos Inc. is a diversified healthcare company focused on the development of novel point-of-care testing (POCT), low-dose VELDONA interferon therapeutics, women's health, pneumonia, Ainos Pen, AI Nose, and other medical technologies. The company was founded in 1984 and is engaged in developing innovative medical technologies for point-of-care testing and safe and effective treatments for various health conditions.

Alamar Biosciences is powering precision proteomics with automated, high throughput solutions for ultra-high sensitivity protein analysis across a range of multiplex levels. Our proprietary NULISA™ Chemistry utilizes a novel sequential capture and release method that significantly reduces background signal and increases the sensitivity and dynamic range compared with standard approaches and allows both qPCR and NGS readouts. The NULISAseq Inflammation Panel contains 200+ important markers related to immune and inflammatory diseases and will run on our ARGO™ System. This innovative platform allows for a fully automated workflow with less than 30 minutes hands on time from sample to data.

Alere is now Abbott! Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 103,000 colleagues serve people in more than 160 countries.

AltheaDx, Inc. is a commercial stage molecular diagnostics company specializing in the field of pharmacogenomics (PGx). IDgenetix® is AltheaDx’s PGx product test for depression and anxiety and is supported by a published/peer-reviewed Randomized Controlled Trial that demonstrated clinical utility over standard of care when physicians used the test prior to prescribing a medication.

Alto Neuroscience is a clinical-stage biopharmaceutical company that integrates the biology of the patient into drug development to improve the lives of people with mental health conditions. Through its AI-enabled biomarker platform, Alto Neuroscience combines rich sources of information on patients’ brain activity and behavior to rapidly develop

At Alveo, we're on a mission to use our open, accessible, and actionable molecular detection platform to detect pathogens before they spread. Our portable, handheld, analyzer and cloud-based data analytics brings molecular detection out of the lab and into the field. Alveo's agile platform can be adapted to detect a wide range pathogens including viruses, bacteria, and fungi. Whether testing a patient at a pharmacy at the point-of-care, chickens pen-side at the point-of-need, or farmers testing crops in-the-field, Alveo's technology brings users real time data precisely when and where it matters most. Partner with Alveo today to bring the power of early detection to your industry. Know Sooner, Act Faster™.

Amprion pioneers Testing for diseases associated with mis-folded proteins. Our flagship product - SYNTap is the assay used by the Michael J Fox Foundations Parkinson's Progression and Markers Initiative (PPMI) to define PD and DLB and its stages. Early diagnosis of synucleinopathies can help guide management, treatment and prognostic discussions. https://www.ampriondx.com

Amron International is a manufacturing company that specializes in high-quality diving, tactical, hyperbaric, and outdoor equipment with over 30 years of industry experience.

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company’s therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain viral protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with OntoChem GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was founded in 1982 and is based in San Jose, California.

Antech Diagnostics, Inc., operates a network of veterinary diagnostic laboratories in the United States. It offers veterinary diagnostics services in the areas of chemistry, hematology and coagulation, endocrinology, serology and immunology, urine and fecal, therapeutic drugs, cytology and histology, and microbiology. The company provides laboratory medicine to veterinarians, as well as provides daily services to animal hospitals, zoos, and government agencies. Subject To: https://www.antechdiagnostics.com/privacy-policy , https://www.antechdiagnostics.com/terms-of-use

Applied Spectral Imaging (ASI) improves patient care through advanced image analysis. Founded in 1993, ASI is a global leader in the development of imaging and analysis platforms for pathology, cytogenetics, and life science research. ASI's GenASIs™ automated imaging platforms for pathology and genetic analysis provide advanced diagnostic aids for pathologists and cytogeneticists, with reproducible and reliable results. The GenASIs platform can be used with most brightfield or fluorescence microscope systems and supports manual and automatic scanning for a wide range of workflows and applications, to best suit the needs, size and budget of any lab. Our GenASIs HyperSpectral™ and HiSKY® platform created the field of hyperspectral karyotyping (SKY) and is still recognized today as the field's most advanced and productive platform. ASI's applications are US FDA cleared for BandView® (karyotyping), FISHView, SpotScan (for CEP XY, UroVysion®, ALK and HER2/neu FISH), and HiPath (for IHC Family: HER2, ER, PR and Ki67). ASI maintains comprehensive patent portfolios in the US, Europe, Japan and other countries. With thousands of Systems deployed worldwide, offices in the US, Europe and Asia, and a network of over 50 distributors, ASI also takes great pride in our outstanding record of service and support. We stand ready to answer your questions and assist you at all times.

Aqtual, Inc. is a precision medicine company using its novel cell-free DNA platform to develop products for chronic diseases and oncology. Our mission is to revolutionize the treatment and management of these conditions by bridging the translational gap between groundbreaking research and practical healthcare solutions.

Arbor Vita Corporation (AVC) is a privately held company committed to making a difference by enabling early and accurate diagnosis and treatment of disease. The company has products on the market or in clinical studies to address global health challenges in the areas of HPV-induced cancer and infectious disease. AVC also has a pipeline of products in development.

ARK Diagnostics Inc. designs, manufactures, and distributes in vitro diagnostic products. ARK's proprietary assays accurately measure drug levels in biological fluids. Clinicians use these measurements to guide dosing decisions for safe, effective, and personalized drug therapy. By optimizing drug levels, clinicians improve outcomes, reduce toxicity, and lower healthcare costs. ARK is dedicated to improving the quality of patient health through better therapeutic drug management. (ARK Diagnostics, Inc. seeks regulatory clearance in the United States and Internationally.)

At Athelas we're bringing simple, life-changing health care products and medical billing services to patients and providers around the globe. Athelas Revenue Cycle Management (RCM): Billing and reimbursement don't have to be painful. Athelas RCM delivers world-class service, maximizes reimbursements, and delivers actionable insights into the financial health of your practice. Athelas prides itself on end-to-end revenue cycle management. This means we cover all aspects of RCM besides simple submission - include denials, working A/R, research, and more as the backbone of your healthcare business. Athelas has powered revenue intelligence for hundreds of healthcare businesses, from small clinics to large health systems. Athelas Remote Patient Monitoring (RPM): We allow healthcare providers to monitor patient vitals like blood pressure, weight, and blood glucose without the patient ever having to enter a clinic, improving patient health and engagement, and reducing hospitalizations. We do this all through a beautifully integrated suite of devices and software tools that provides access to state-of-the-art technologies and groundbreaking AI powered analysis.

Focusing on developing the best nucleic acid amplification and detection technologies for clinical molecular diagnostics - COVID-19 (FDA EUA Approved), Non Invasive Prenatal Test, HPV Detection, STI, NGS Cancer Panel (Lung, Breast, Colorectal), and many more.

AutoGenomics is a biotechnology company that offers an automated microarray based multiplexing molecular diagnostic platform to assess disease signatures with novel genetic biomarkers in the areas of women’s health, cancer and personalized medicine.

Autonomous Medical Devices Incorporated (AMDI), with its principal place of business in California, employs a world class team of engineers, scientists, clinicians, and manufacturing experts dedicated to the development and manufacture of point-of-care diagnostic devices using breakthrough microfluidics, protein engineering, and data/cloud connectivity. AMDI will launch its first products from its ISO:13485 certified 110,000 square foot facility in Santa Ana, CA.

Avails Medical, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenge of antibiotic resistance and health-care associated infections.

Avellino turns genomic analytics into actionable healthcare insights, creating a healthier future for all. Powered by artificial intelligence and machine learning, its genetic discovery engine drives disruptive healthcare innovations. Avellino’s expertise spans a broad spectrum of healthcare specialties, including the impact of genetics in ophthalmology, oncology, pathogenomics and infectious diseases. As a global leader in leveraging artificial intelligence-powered algorithms, Avellino’s diagnostics provide eye care professionals with personalized genetic data to predict eye disease, prevent disease progression and ultimately preserve vision. Avellino has completed more than one million genetic eye tests since 2008, commercialized in the United States, South Korea and Japan. Its world class CLIA-certified laboratory in California has tested more than four million patients for COVID and RSV. Avellino’s research and development team has made groundbreaking discoveries leveraging genetic data, with programs in early detection of oncology, a polygenic risk analysis for glaucoma, and a siRNA gene-silencing therapeutic for the treatment of granular corneal dystrophy type II (currently in preclinical development). With a focus on health equity, Avellino prioritizes the inclusion of ethnically diverse populations in its studies to maximize the impact of its genomics breakthroughs for global healthcare. Avellino is headquartered in Silicon Valley, California, with operations in Korea, Japan, and the UK.

BillionToOne is a precision diagnostics company that quantifies biology to create powerful molecular diagnostics. They are focused on moving Prenatal Screening and Liquid Biopsy forward to improve disease detection.

BioAmp Diagnostics is committed to preventing the misuse and overuse of antibiotics in healthcare through the development of innovative diagnostic tools, that will give medical providers the information they need to correctly treat an infection.

Biocare Medical LLC is an innovator in automated immunohistochemistry (IHC) instrumentation, and the full range of reagents for IHC and in situ hybridization (ISH; RISH) testing. Biocare pioneered multiplex IHC detection which accelerates turnaround time, increases instrument productivity and reduces reagent consumption and cost by 50% or more. Multiplex IHC allows pathologists to visualize more than one marker on a tissue at a time, allowing higher confidence for critical differentiation. Biocare's intelliPATH FLX is the only completely open, continuous random access IHC instrument available. The company’s customers come from clinical and research environments that do tissue based testing and include histology laboratories, pharmaceutical and biotechnology companies; CROs; and academic, government and military labs. Biocare Medical offers an expanding portfolio of products for the rapidly growing cancer and infectious disease diagnostic and research markets. Biocare medical is headquartered and has manufacturing facilities in Concord, Calif., and has a global distribution network. See biocare.net and slidestainer.com for more information. NOTE: Biocare Medical, the Biocare Medical logo, and intelliPATH are trademarks of Biocare Medical LLC.

BioCheck develops and manufactures high-quality immunoassay kits for the worldwide healthcare markets in their cGMP and ISO 13485 certified facility in the San Francisco Bay Area. BioCheck also provides custom immunoassay development and contract manufacturing services to the diagnostic and research industries.

The heart of BioFluidica's CTC (Circulating Tumor Cells) system, is a highly efficient CTC capture bed, comprised of 50 to 500 sinusoidally-shaped channels. These channels are coated with antibodies, which isolate specific CTCs from whole blood. The antibodies are chemically immobilized onto the surfaces of the capture bed using BioFluidicas patented technology.

Biolinq has created a new Biowearable experience by using an array of electrochemical sensors so small you can barely feel them. Our metabolic health sensors work together to provide maximum reliability for continuous sensing applications. With the potential of multiple analytes such as glucose, ketones, and lactate, we provide an entirely new user experience with actionable metabolic health insights. Over the next 10 years we intend to bring Biosensing and Biowearables mainstream. We are dedicated to the personal and professional growth of all our team members and strive to create a positive and creative work environment.

Biomerica, Inc. (www.biomerica.com) is a global biomedical company that develops, manufactures and markets advanced diagnostic products used at the point-of-care (in home and in physicians’ offices) and in hospital/clinical laboratories for the early detection of medical conditions and diseases. The Company’s products are designed to enhance health and well-being, while reducing total healthcare costs. Biomerica primarily focuses on products for Gastrointestinal Disease, Diabetes and esoteric testing. The Biomerica InFoods® IBS product identifies patient specific foods that when removed may alleviate an individual's IBS symptoms. This patent pending diagnostic guided therapy is designed to allow for a patient specific guided dietary regimen to improve Irritable Bowel Syndrome (IBS) outcomes. The point-of-care product is being developed to allow physicians to perform the test in-office using a finger stick blood sample while a clinical lab version of the product will be the first for which the company will seek regulatory approval. A billable CPT code that can be used by both clinical labs and physicians'​ offices is available for InFoods® diagnostic products. Since the InFoods® product is a diagnostic guided therapy and not a drug, it has no drug type side effects.

Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. Our mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. We offer OGM solutions for applications across basic, translational and clinical research. Bionano also offers an industry-leading, platform-agnostic genome analysis software solution, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through our Bionano Laboratories business, wey also offer OGM-based diagnostic testing services.

Specializing in Creating and Improving Biosensors with Synthetic Biology. Winner of LymeX Diagnostics Prize

Boundless Bio is discovering and developing novel cancer therapeutics based on the role of extrachromosomal DNA (ecDNA) in driving tumorigenesis, resistance and recurrence. When DNA in cancer cells comes off chromosomes, “extrachromosomal DNA (ecDNA),” it becomes unbound and unwound, thereby enabling numerous copies of cancer-causing genes, driving cancer cells to grow and allowing them to resist treatment. At Boundless Bio, we are counterattacking this ecDNA phenomenon with boundless innovation and boundless energy to develop powerful new cancer medicines that eliminate cancer cells’ ability to employ ecDNA to survive. Our Culture: At Boundless, you’ll experience what it means to be out in front of the wave. Our unprecedented science takes us to new shores, and our team navigates the best breaks. We’re leaders in our field, and we’re dedicated to the cause of understanding and treating intractable cancers. Every employee at Boundless makes an unbridled impact on our capabilities and our culture. We’ll help you expand your abilities and defy your bounds by providing meaningful work and unbounded opportunities. Career development is essential at Boundless. We’re all in on this fight against cancer– collaboration is requisite to our success. We have a team of people who ask, offer, and accept help without regard for ego. We know that receiving support is energizing, and giving help is fulfilling. We are inspired by the patients who are reliant upon our success. At Boundless, we’re all in. We are unbound by convention, bound to save lives. Career Inquiries careers@boundlessbio.com General Information Inquiries info@boundlessbio.com

Bright Uro is an early-stage medical technology company headquartered in Irvine, CA. They are building the next generation of diagnostic devices for Urology.

Market opportunities created by evolving legislation legalizing recreational use of cannabis is generating a significant need for advances in rapid and accurate drug testing technology. Buzzkill Labs is developing next generation technology that will combine patented noninvasive sample collection methodology with scientifically validated laboratory detection and quantitation technology. Buzzkill Labs products will address the growing need for:SAFETY IN THE WORKPLACESUSPECTED IMPAIRED DRIVING BY LAW ENFORCEMENTFAST AND ACCURATE TESTING BY MEDICAL AND DRUG TREATMENT CENTERS

Cadex Genomics develops molecular diagnostic tests to guide cancer treatment using liquid-based technology to provide personalized insight into the therapy response. By combining proven approaches to measuring DNA with cutting-edge technology to improve accuracy and sensitivity Cadex Genomics provides unique insight into therapy response using simple blood draws. Alibrex is a blood-based assay, developed to help physicians identify patients who are not responding to drug therapy. The test is optimized to maximize NPV, that is, minimize the number of false non-responders.

The California Animal Health and Food Safety Laboratory System (CAHFS) is the backbone of California's warning system that helps to protect the health of California's livestock and poultry. CAHFS serves the people of California by safeguarding the public health with rapid and reliable diagnoses for animal diseases including those affecting humans. CAHFS operates in partnership with the California Department of Food and Agriculture, UC Davis, veterinarians, and livestock and poultry producers. CAHFS provides quality services that protect animal health and performance, public health and the food supply.Located on the University of California, Davis campus, the Davis laboratory provides livestock, equine and avian necropsy, histopathology, immunohistochemistry, electron microscopy, toxicology, serology, microbiology and virology testing on site. Specialty services for equine performance chemistryand pharmacology are also located at the Davis facility.CAHFS Davis offers:American College of Veterinary Pathologists board certified diagnosticiansAmerican College of Veterinary Microbiologists board certified microbiologistAmerican Board of Veterinary Toxicology board certified toxicologistExperts in poultry/avian, horse, cattle, pig, llama, alpaca, sheep, goat, exotics and wildlife diseasesForeign animal disease trained diagnosticians on siteComprehensive reports which include gross examination, histopathology and testing in other disciplines as neededNational Poultry Improvement Plan approved site for Salmonella, Mycoplasma and Avian Influenza testing

CareDx: Transforming Transplant Patient Care Through Novel Surveillance Management Solutions CareDx, Inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. By combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, CareDx is at the forefront of organ transplant surveillance and pre-transplant HLA typing solutions. NASDAQ:CDNA About AlloSure® AlloSure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. AlloSure is a clinical-grade, proprietary Next-Generation Sequencing (NGS) based test to detect donor-derived cell-free DNA (dd-cfDNA) in order to identify organ injury in kidney transplant recipients. AlloSure is analytically validated as a sensitive, specific, and precise measurement of dd-cfDNA. AlloSure detects active rejection (acute active ABMR, chronic active ABMR, or TCMR) with high accuracy, outperforms serum creatinine in kidney transplant recipients, and is highly sensitive in distinguishing ABMR from no ABMR. AlloSure is performed in the CareDx CLIA-certified laboratory. http://www.allosure.com/ About AlloMap® AlloMap Molecular Expression Testing is a non-invasive blood test used to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection at the time of testing in conjunction with standard clinical assessment. AlloMap testing measures the expression levels of 20 genes from a blood sample. The combined expression of these genes is represented as an AlloMap test score. AlloMap is performed in the CareDx CLIA-certified laboratory and has been commercially available in the United States since 2005. AlloMap was cleared by the U.S. Food and Drug Administration in 2008 and was CE marked for the European Union in 2011. Use of AlloMap is also included in the International Society for Heart and Lung Transplantation (ISHLT) Practice Guidelines, published in August 2010, the worldwide standard for the care of heart transplant patients. http://www.allomap.com/

Cellecta provides HT loss-of-function genetic screening services for the discovery and functional characterization of novel therapeutic targets. We offer pooled lentiviral shRNA and CRISPR libraries, pooled library screening and analysis by NGS, targeted RNA-Seq for biomarker discovery, lentiviral reagents, and stable cDNA, shRNA, and CRISPR constructs and isogenic cell lines.

CellMax Life is a leading cancer diagnostics company whose mission is to transform how cancer is diagnosed and managed with globally affordable non-invasive tests for early cancer detection and management. CellMax's unique expertise in both Circulating Tumor Cell and Next Generation Sequencing of DNA and circulating tumor DNA (ctDNA) has enabled multiple highly effective precision medicine solutions for healthy people as well as patients diagnosed with cancer.

Celula is a biotechnology company that offers Celula IDA, Integrated Diagnostic Accuracy, providing better solutions for prenatal testing and novel approaches to cancer detection.

Cepheid is dedicated to improving healthcare by pioneering molecular diagnostics that combine speed, accuracy, and flexibility. The company's GeneXpert® systems and Xpert® tests automate highly complex and time-consuming manual procedures, providing A Better Way for institutions of any size to perform world-class PCR testing. Cepheid’s broad test portfolio spans respiratory infections, blood virology, women’s and sexual health, TB and emerging infectious diseases, healthcare-associated infectious diseases, oncology and human genetics. The company’s solutions deliver actionable results where they are needed most – from central laboratories and hospitals to near-patient settings. For more information, visit http://www.cepheid.com. Cepheid is proud to be a part of Danaher. Danaher’s science and technology leadership puts Cepheid’s solutions at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers. Together with Danaher’s other businesses across Biotechnology, Diagnostics, and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day.

Clear Labs harnesses the power of next-generation sequencing (NGS) to simplify complex diagnostics for clinical and applied markets. By creating a fully automated platform that brings together DNA sequencing, robotics and cloud-based analytics, Clear Labs democratizes genomics applications to deliver increased clarity. Clear Labs’ turnkey platform accelerates outcomes and improves accuracy - from food-borne pathogens to infectious diseases, including SARS CoV-2. With a novel approach, Clear Labs is helping the world better understand, track and mitigate tomorrow’s novel pathogens.

Cognoa innovates solutions for child developmental health. We build breakthrough products like Canvas Dx, the first and only FDA authorized autism diagnostic for children ages 1.5 to 6 years that uses responsible AI to empower doctors to quickly, accurately, and fairly diagnose developmental risk without bias. Our digital solutions are child centric and designed to find, assess, and treat developmental concerns early, within the time windows that will yield the optimal outcomes. Our proprietary "whole child" approach to AI fuels our pipeline of diagnostic and therapeutic products for autism, speech and language, ADHD, childhood anxiety, and more. For more information, visit www.cognoa.com.

Cognos Therapeutics Inc. (Cognos) is an advanced medical device company focused on creating unique technologies to radically advance the diagnosis and treatment of neuropathic diseases including tumor-based brain and spinal cancers, degenerative cognition disorders (such as Alzheimer’s and Parkinson’s disease), cerebral trauma occurrences (such as epilepsy and stroke) as well as other Central Nervous System afflictions.

Diagnostics

CTK Biotech is a biotechnology company that specializes in medical diagnostics for healthcare applications.

Cureline is a global precision and translational medicine CRO located in California (USA). With more than a hundred validated clinical partners in 20 countries, HBS repository in San Francisco Bay area and excellence in laboratory services, Cureline provides a full spectrum of translational research services: global regulatory affairs, custom protocol HBS biobanking, histopathology & digital pathology, molecular and cellular lab services, small animal studies and cell and gene therapy (ATMP) solutions. Since 2003 Cureline is a global leader in commercial biobanking and biomedical research services with a focus on targeted drug R&D, biomarker research and companion diagnostics development.

CureMatch is a leader in AI-based precision medicine, digital decision support solutions that support cancer treatment. Created to empower oncologists with world-class research and sophisticated AI algorithms, the CureMatch Decision Support System assists the doctor with understanding therapeutic options that are personalized to the unique molecular profile of the individual patient's tumor.

Cytovale is a medical diagnostics company focused on providing a more rapid and insightful way to diagnose fast-moving and immune-mediated diseases. Our FDA cleared IntelliSep test is pioneering a new way of quickly and accurately analyzing white blood cells to stratify a patient’s risk of sepsis by performing a biomechanical evaluation of white blood cells collected from a standard blood draw in under 10 minutes. Cytovale’s first market application will be for sepsis, one of the fastest-moving, most lethal conditions in the world. Sepsis, a dysregulated immune response to infection, is often difficult to quickly and accurately diagnose. Sepsis is the no. 1 cause of death in hospitals, taking the lives of 270,000 people every year in the U.S. – more than opioid overdoses, prostate cancer, and breast cancer combined. Mortality from sepsis increases as much as eight percent with every hour of delayed treatment, and as much as 80 percent of sepsis deaths could be prevented with rapid diagnosis and treatment, making early detection essential. Cytovale aims to provide critical insight for early identification of patients at risk of having sepsis, in the time needed for it to be useful. Follow us on Twitter: twitter.com/cytovale

Darmiyan is a pioneering brain technology (deep-tech) company based in San Francisco, California, focused on developing innovative and rapidly scalable products for brain health screening and monitoring. The company's mission is to enhance brain health, equipping physicians with tools for precise, personalized patient care, thereby optimizing health outcomes. Darmiyan's first product, BrainSee, is FDA-approved and available to physicians to aid in prognosis of patients diagnosed with amnestic mild cognitive impairment (aMCI).

DC3 Therapeutics is a full service Contract Research Organization (CRO). We offer a full set of services necessary for drug discovery, pre-clinical and IND enabling studies. Our services include histology and in vitro pharmacology as well as molecular, cellular, and micro-biology. We are happy to work with our clients to custom tailor experiments according to their research and development goals. Because we understand that drug development is a fast paced and demanding environment, we guarantee that our services are performed accurately. And to ensure a quick turn-around time, each customer is assigned a secured DC3 account to conveniently download data, schedule pickup, and submit inquiries. Our team, who are committed to superior customer service, has extensive experience in the drug development process and the pharmaceutical industry. You can rely on us to deliver quality data.

We are a well-funded stealth biotech company backed by some of the most experienced operators and investors in the biotech industry. Our co-founders are highly experienced researchers, clinicians, and entrepreneurs, on a mission to improve precision medicine with cutting-edge genomic technology.

DiaCarta is a translational genomics and personalized diagnostics company that provides ultra-sensitive detection tools for cancer diagnosis, therapy identification and prognosis monitoring. Our mission is to provide ultra-sensitive and advanced technologies that will redefine the way molecular diagnostics and translational genomics impact healthcare treatment plans and the well-being of individuals around the world. To learn more, visit http://www.diacarta.com.

Diagnostic BioSystems is a leading developer of specialty Immunohistochemistry reagents. The company is dedicated to high quality antibody production and development of novel multiplex staining reagents. Building on its strong global presence, Diagnostic BioSystems produces novel, clinically relevant tools for pathology market including: monoclonal and polyclonal antibodies, a wide range of detection systems and ancillary reagents for high quality immunostaining. Custom Monoclonal and Polyclonal Antibody Production Services include peptide synthesis, in vitro and in vivo antibody production, purification and conjugation. Diagnostic BioSystems is an FDA registered medical device manufacturer, operating under FDA 21CFR Part 820 Quality System Regulations and certified under ISO 9001:2008 Quality Management System International standards, manufacturing CE marked medical devices, for use in the European market.

Diazyme uses its proprietary enzyme technologies to develop diagnostic reagents which can be used on most automated chemistry analyzers in user-friendly formats. Diazyme's products include test kits for diagnosis of cardiovascular disease, liver disease, cancer markers, renal disease, diabetes, and electrolytes.Diazyme DZ-LITE SARS-CoV-2 IgG, IgM CLIA Kits

We are the first gut microbiome, genetics-based virtual care platform for people struggling with polychronic mental & physical illness associated with weight and gut. We use AI to harness clinical, genetic, gut microbiome, food and behavioral signals to target the root cause of illness. We deliver tailored whole-person care, including remote monitoring, food-as-medicine, pharma reduction, behavioral coaching support, and care coordination. We use AI to harness food information, clinical, genetic, gut microbiome, and behavioral signals, to deliver tailored holistic care, including food as medicine, behavioral coaching support, remote monitoring, and care coordination, to target the root cause of illness. Our customers love us because we acknowledge their unique physiology, lifestyle, food habits and deliver data-driven personalized care supported by specialist coaches that puts the customer in charge.

Diagnostic testing for patients across all rare genetic diseases, including Cystic fibrosis, Fabry disease, Epilepsy, Hemophilia, all types of hereditary cancers, and cell and gene therapy.

DotLab measuresdisease-specific biomarkers and appliesadvanced biostatisticsfor non-invasiveendometriosis​ testing. ​​​​​​

At Drawbridge, we’ve created the OneDraw™ technology to transform the way blood is sampled and shipped. But that’s just the start. Our ultimate goal? To give everyone, everywhere access to the powerful health information within their own bodies.

Earli mission is to make cancer a benign experience. Rather than rely on biomarkers that cancer may - or often may not - naturally provide, Earli's technology *forces* cancer cells to make a synthetic, non-human biomarker using gene therapy approaches. It's called a Synthetic Biopsy. It can then localize the cancer in a PET scanner. Earli has been funded by Andreessen Horowitz's Bio Fund, Khosla, Perceptive Advisors, Casdin Capital, Sands Capital, Marc Benioff, Menlo Ventures, ZhenFund. Earli is based in the West Coast’s prime biotech hub in South San Francisco.

Edan is a healthcare company dedicated to improving the human condition around the world by delivering value-driven, innovative and high-quality medical products and services. For over 20 years, Edan has been pioneering a comprehensive line of medical solutions that address a broad range of healthcare practices including Diagnostic ECG, OB/GYN, Ultrasound Imaging, In-Vitro Diagnostics, Patient Monitoring, Point-of-Care Testing, and Veterinary. Healthcare professionals around the world depend on Edan's breakthrough medical technologies and outstanding customer support. Till now, EDAN has reached over 170 countries and areas and 40,000 medical facilities with Industry Leading Healthcare solutions.

Eikon Therapeutics is a biopharmaceutical company that develops live-cell resolution microscopy and engineering for drug discovery. They are pioneering a new method of drug discovery based on tracking and measuring movement of molecules within living cells. The company leverages superior engineering and high-performance computing to analyze single molecules and discover innovative medicines.

Emerge Diagnostics is a medical devices company that offers an FDA-registered Electrodiagnostic Functional Assessment (EFA) device for assessing muscle activity and differentiating between acute and chronic injuries.

We are a biotechnology company offering end-to-end solutions in molecular diagnostic for oncology and hematology by providing hardware, reagents and software. Starting from automated nucleic acid extraction and culminating in genomic interpretation with its proprietary software embedded throughout entire workflow, EntroGen solutions are designed to be accurate, economic and scalable. EntroGen sells CRCdx®, a U.S. FDA-approved product.

Epic Sciences, Inc. is developing novel diagnostics to personalize and advance the treatment and management of cancer. Epic’s mission is to enable the rapid and non-invasive detection of genetic and molecular changes in cancer throughout a patient’s journey. The company was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells (CTCs). Our technology helps match patients to targeted therapies and monitor for drug resistance, so that the best treatment path can be chosen at every clinical decision point. Today, we partner with leading pharmaceutical companies and major cancer centers around the world. Epic’s goal is to commercialize our technology to increase the success rate of cancer drugs in clinical trials and improve patient outcomes by providing physicians with real-time information to guide treatment choices. For more information please contact us at info@epicsciences.com

Epinex Diagnostics is a medical device company that specializes in the development of innovative rapid tests that target major deficiencies in existing healthcare markets. Our proprietary platform for rapid tests uses existing technologies to create unique quantitative diagnostic tests for the point-of-care (POC) and over-the-counter (OTC) markets. The Company’s flagship product is the G1A™ Rapid Diabetes Monitoring Index Test, a patented monthly test for diabetes monitoring. The Test has the potential to improve diabetes care and have a successful impact on the current worldwide diabetes epidemic, the most significant chronic disease affecting the world today. Epinex Diagnostics, Inc. is located in Tustin, California, adjacent to the University of California, Irvine, in the heart of the Southern California biomedical industry.

At Exact Sciences, our purpose is to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment. We're hiring! Our organization offers something for everyone, at all stages of careers and from all backgrounds. Let's take on cancer, together.

Exagen Inc. is a Patient Focused, Discovery Driven, CLIA-certified, CAP-accredited laboratory with a growing menu of proprietary, internally developed tests focusing in the area of Rheumatology and Autoimmune diseases. Committed to Personalized Medicine, our AVISE tests are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management.

Exai Bio is a next-generation liquid biopsy company. Our mission is to enable a world where cancer can be detected early, diagnosed accurately, treated in a personalized and targeted way, and ultimately cured. The company's proprietary RNA and artificial intelligence-based liquid biopsy platform delivers clinical insights into cancer biology to enable the earliest, most accurate diagnosis of cancer. Exai Bio was founded with technology from the UCSF laboratory of Dr. Hani Goodarzi, and consists of veteran leaders in the RNA biology, liquid biopsy, and artificial intelligence/machine learning fields from both academia (UCSF, Stanford, MIT) and industry (Bluestar, CareDx, Evidation, Google, 23andMe, Deep Genomics). Exai Bio is supported by leading life sciences and tech investors including Section 32, Casdin Capital, and Two Sigma Ventures, who have been integral to advancing cancer diagnostics, and artificial intelligence and machine learning technologies. We know that people are our greatest asset and we are rapidly building a rock-star team of talent. Our people are driven by the mission, inspired by the vision of the future, and are committed to living our core values (integrity, openness, teamwork, exploration, and kindness) that connect us to our work and to one another. What We Value Our core values represent what we stand for as a team. This is what we believe in. Everyday, we strive to align our behaviors to these core values in everything we do. Integrity – Our thoughts and actions are true to science and to people. We do the right thing. Openness – We recognize and respect our differences – and embrace learning from them. Teamwork – We are team players who trust and respect each other. Exploration – We are explorers, putting curiosity into action. Kindness – We are kind whenever possible – and we believe it's always possible.

Challenges with physical cell isolation limit adoption of single-cell sequencing. So we figured out how to prepare complete libraries within intact cells.

Fore Genomics, a clinically-focused genetics company, has launched FORESITE 360, a leading-edge product offering clinical-grade, in-depth sequencing for the littlest patients. Focusing on newborns and children, a simple cheek swab sample provides doctors and parents with valuable genetic insight into a child's potential for future diseases based on their DNA. Backed by the reliability of CLIA-certified and CAP-approved labs, FORESITE 360 is designed to offer a complete genetic profile of your child, unlocking a lifetime of health insights. FORESITE 360 incorporates ongoing re-analysis of DNA, allowing doctors to take practical steps toward managing any detected medical conditions. Without adding a single item to their to-do list, clinicians can now add value for their patients with leading-edge sequencing, high-quality genetic counseling, and annually updated analysis.

Freenome is a private biotech company focused on developing blood tests to detect cancer early and make screening accessible for everyone.

Our mission is to develop flexible and affordable diagnostics and therapeutics that improve the everyday lives of those around us. Founded in 2011, Fulgent has evolved into a premier, full-service genomic testing company built around a foundational technology platform. Through our diverse testing menu, Fulgent is focused on transforming patient care in oncology, anatomic pathology, infectious and rare diseases, and reproductive health. We believe that by providing a wide range of effective, flexible testing options in conjunction with best-in-class service and support, we can redefine the way medicine is managed for patients and clinicians alike. - Our Products & Services - Fulgent Genetics https://www.fulgentgenetics.com/ Fulgent Oncology https://fulgentoncology.com/ Fulgent BioPharma https://biopharma.fulgent.com/ Picture Genetics https://picturegenetics.com/ HelioLiver https://www.helioliver.com/ Fulgent is a CLIA-certified and CAP-accredited laboratory. _____________ NASDAQ: FLGT

GenBody is a diversified manufacturer of diagnostic tests for over 78 human diseases. With more than 20 years combined experience in the diagnostic industry and through its vast network between several key institutes, universities and hospitals, our core strength is in R&D. GenBody specializes in developing monoclonal antibodies and recombinant antigens in-house at our facility in South Korea. Recently, the US FDA granted Emergency Use Authorization to GenBody's COVID-19 Ag point-of-care antigen test for SARS-CoV-2 infection. The immunochromatographic rapid diagnostic test is designed for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct nasopharyngeal swab specimens. The test can be performed by a healthcare professional and an at-home test is in development for future use. Earlier this year, GenBody received a US National Institutes of Health contract for the US production of a visually read, single lateral flow rapid test system for SARS-CoV-2. Located in Jurupa Valley, California, the US factory is expected to be complete in Q3 2021. GenBody is rapidly expanding its footprint in the US and expects to increase its headcount in regulatory, product development and sales. For inquires regarding opportunities join our team, please call 949-561-0664 or jobs@genbodyamerica.com. For partnership opportunities, call 949-561-0664 or email partnerships@genbodyamerica.com.

Gene Bio Medical is dedicated to the research & development, manufacturing, and commercialization of high-precision, low-cost, and effective diagnostic technologies that improve human health and enable the response capabilities towards a variety of diseases. We have a vision to revolutionize the healthcare industry and innovate for the greatness of our community. Founded by a group of talented research scientists, practitioners, and business experts, Gene Bio Medical has rapidly developed into an industry leader in molecular diagnostics technologies. The company manufactures and markets its own products, develops new innovative products, and collaborates with the healthcare ecosystem to bring innovations to people.

Glycominds, a commercial stage diagnostics company, develops and commercializes autoimmune and chronic inflammatory disease biomarkers with a distinctive focus on the Inflammatory Bowel Disease (IBD).

Guardant Health is a leading precision medicine company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, we're transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant Health has commercially launched Guardant360®, Guardant360® CDx, Guardant360 TissueNext®, Guardant360 Response™, and GuardantINFINITY™ tests for advanced-stage cancer patients, and Guardant Reveal® for early-stage cancer patients. The Guardant Health screening portfolio, including the FDA-approved Shield™ test, aims to address the needs of individuals eligible for cancer screening. Important Note for Job Applicants: Guardant Health is aware of recruiting scams where unauthorized individuals use the company's name in fraudulent emails, job postings, and social media messages. Please note that Guardant Health will never ask for money or credit card information during the job application process, nor does the company communicate with candidates via online chatrooms or personal email accounts such as Gmail or Hotmail.

Hardy Diagnostics offers products and services related to microbiology. The company's products are used in pharmaceutical microbiology, food and beverage microbiology, and clinical microbiology.

Histologics has developed a series of Tissue-Based Technology™ products that leverage the benefits of our patented Kylon™ medical material. Kylon™ medical material incorporates hundreds of "micro-curettes" which are incorporated into single-use, disposable devices used for biopsy as well as wound care and debridement. Kylon™ is common to all Histologics single-use, disposable devices and offers distinct benefits over legacy "metal" devices and procedures. Within the Gyn field, Kylon™ is rapidly expanding use in epithelial curettage and colposcopy procedures, where Kylon™ yields tissue samples that rival more traditional, invasive techniques using antiquated metal cutting tools, whose use and success are subject to sharpening, sterilization, and general management (cost of use). Kylon™ is designed with the patient, physician, and pathologist in mind. Our devices are minimally invasive, yet yield tissue samples that statistically compare to your current methodologies. The use of Kylon™ devices is also rapidly evolving in the field of wound care and debridement. Kylon™ devices enable debriding with more control and less trauma than a scalpel or curettage techniques. Kylon™ also provides another key benefit to impart agitation to the underlying tissue. This agitation through micro-punctation of the wound site, along with the associated friction which produces small amounts of heat, works to stimulate new tissue development, which may lead to faster more comprehensive healing in less time (and less patient trauma when compared to scalpel-based procedures). Visit www.Histologics.com (GYN) or www.HistologicsWC.com for more information. Watch our videos (below). Fill out our sample request form today! Dr. Neal Lonky, MD MPH is nationally recognized for his work in female health, where he specializes in early cancer detection.

Human Longevity, Inc. ™ (HLI) is the genomics-based, health intelligence company creating the world’s largest and most comprehensive database of whole genome, phenotype and clinical data. HLI is developing and applying large scale computing and machine learning to make novel discoveries from these data to generate personalized health insights. Our goal is to extend healthy human life by revolutionizing human health and transforming the practice of medicine. Our DNA determines so much about each of us, but other factors can also influence our health. HLI is focused on compiling and analyzing more genotypic and phenotypic data because the combination of both enables us —to generate unprecedented insights and accelerate our understanding into what makes us who we are and what we can change for a life better lived.

Founded in 1981, HYCOR Biomedical is a global manufacturer and marketer of in vitro diagnostic products. Since its founding, HYCOR has served the allergy diagnostic testing needs of clinical laboratories, hospitals and doctors'​ offices worldwide. The recently launched NOVEOS™ builds upon 40 years of experience in specific IgE testing, and supplements the Company’s existing line of HYTEC® products. The company is focused on delivering NOVEOS, a new generation of fully-automated allergy system that solves the shortcomings of today's technology, with 1/10th the sample requirement and negligible interference issues. For more information, please visit www.HYCORbiomedical.com.

Hygiena delivers rapid microbial detection, monitoring, and identification solutions to a wide range of industries, including food and beverage, healthcare, hospitality, pharmaceuticals, and personal care. Utilizing advanced technologies and patented designs, Hygiena provides industry-leading ATP monitoring systems, PCR-based pathogen detection and characterization systems, allergen tests, environmental collection devices, and more. Hygiena is committed to the mission of providing customers with high-quality innovative technologies that are easy-to-use and reliable, backed by excellent customer service and support. Headquartered in Camarillo, California with multiple offices around the world including Wilmington, Delaware, United Kingdom, Spain, Canada, Mexico, Australia, Brazil and China, and over 180 distributors in more than 100 countries worldwide, Hygiena branded products span the globe.

At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. Illumina's innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.

ImaginAb is a clinical stage, revenue-generating global biotechnology company developing the next generation of imaging agents and radiopharmaceutical therapy (RPT) products through its proprietary minibody and cys-diabody platforms. The lead candidate 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™) imaging agent is currently in Phase II clinical trials and has been licensed by numerous pharmaceutical and biotech companies for use in imaging within their immunotherapy clinical trials, primarily in oncology.

Imagion Biosystems is dedicated to providing tools to find and eliminate cancer. We are a multidisciplinary team with expertise in the physics of magnetic fields and nanotechnology and the medical application of these fields. Our focus is in the rapidly emerging field of nanobiotechnology with an emphasis on the early detection and localization of cancer and other human diseases. Our technologies also hold the promise of providing image-guided therapy for the treatment of these diseases, as well as providing new methods for therapeutic intervention. Our proprietary technologies and methods employ magnetic nanoparticles targeted towards cells associated with cancer and other diseases and provide the ability to detect these cells using highly sensitive magnetic sensors. These methods have numerous preclinical and clinical applications. Preclinical research projects have focused on the early detection of breast cancer, ovarian cancer, and prostate cancer.

Since 1976, Immunalysis Corporation has focused on identifying and meeting the demands of the toxicology marketplace. With an expansive line of ELISA and Homogeneous Enzyme (HEIA™) assays, plus Quantisal™ – Immunalysis' proprietary oral fluid collection device, as well as automation tools and confirmation support, Immunalysis provides forensic toxicologists with powerful, comprehensive drug testing solutions.

Quality is our Heritage - Service is our Passion Immuno Concepts is a privately hold company that specialises in the manufacturing of in vitro diagnostics for Autoimmune Diseases since 1980. Our product portfolio comprises reagents and instrumentation such as a unique automatic microscope scanning system for immunofluorescent slide tests. Hospital labs all over the globe and major lab chains trust in our quality and service.

Aristo Vojdani, PHD, MSC, CEO Immunosciences Lab. Inc. located in Los Angeles is part of the Medical and Diagnostic Laboratories Industry.

IncellDx is a molecular diagnostics company dedicated to revolutionizing healthcare one cell at a time. By combining molecular diagnostics with high throughput cellular analysis, we focus on critical life threatening diseases such as COVID-19, HIV/AIDs, lung cancer, breast cancer, bladder cancer, HPV/cervical cancer, head and neck cancer, ovarian cancer, hepatitis, and organ transplant infections. Our proprietary diagnostic method provides specific molecular details about each and every cell. This technology now made available through IncellDx, is capable of revolutionizing the field of molecular diagnostics, one cell at a time.

Indi Molecular is developing protein catalyzed capture (PCC) agents as a small synthetic molecule replacement for antibody-based therapeutics. PCCs are poised to play a central role in therapy given their ability to be deployed as both a precision in vivo PET diagnostic and as a targeted therapeutic. For radiotherapy this dual role is accomplished by choice of the complexed radionuclide sharing the same chelation chemistry. Chemotherapy can similarly be specifically delivered to diseased cells by the protein catalyzed capture technology. The company launched in 2013 with a $1.8 million seed round, followed by an $11.5 million Series A in 2017.

Inflammatix is developing an innovative point-of-care instrument platform to be used with a test to aid in the diagnosis of acute infection and sepsis by harnessing the immune system to deliver advanced immune response diagnostics. Our test rapidly informs the clinician about the likelihood of bacterial or viral infection and the need for ICU level care in the emergency department. Faster results may translate into more timely and appropriate therapy and level of care decisions. *Products in development, are not for sale, and do not have marketing approval or clearance from regulatory authorities in any jurisdiction.

InterVenn was co-founded by Nobel Laureate Dr. Carolyn Bertozzi, world-class scientist, and distinguished professor Dr. Carlito Lebrilla and leading AI/ML expert Aldo Carrascoso on the belief that no one should ever be blindsided by disease. We are focused on decoding the glycoproteome as a rich source of biological insight. Thanks to the use of artificial intelligence (AI), we have pioneered a proprietary technology platform, GlycoVision™, to tap into this layer of biology at a clinically meaningful scale. GlycoVision is capable of producing a robust pipeline of powerful clinical applications, ranging from early disease screening to diagnostics and potentially therapeutics. The GlycoVision platform is accessible to industry partners seeking to discover novel biomarkers from as little as 50 µL of serum or plasma.

Intrinsic LifeSciences LLC provides superior, innovative & patent-protected research test kits and certified diagnostics & clinical research CLIA services for hepcidin and erythroferrone (ERFE), the key indicators of anemia, inflammation and pregnancy disorders. Our CAP accredited clinical lab, IntrinsicDx™, offers the Intrinsic Hepcidin IDx™ Test service. We also provide RUO immunoassay testing for other related biomarkers. To learn more visit www.intrinsicdx.com, www.intrinsiclifesciences.com.

Invivoscribe® is a global leader dedicated to Improving Lives with Precision Diagnostics®, advancing the quality of healthcare by providing innovative products and clinical services for oncology. Our Streamlined CDx® (companion diagnostic) model accelerates the development of novel therapeutics, enabling personalized approaches to patient care. With products manufactured in our state-of-the-art cGMP facility, we provide a comprehensive range of platform agnostic assays, reagents, controls and software for clonal gene rearrangements, translocations, gene mutation testing, and measurable residual disease (MRD). Invivoscribe’s products consistently surpass industry and regulatory standards and play a crucial role in identifying, stratifying and monitoring hematologic cancers, enabling scientific advancements and empowering clinicians to make informed treatment decisions. Our subsidiary, the Laboratory for Personalized Molecular Medicine® (LabPMM®), offers extensive clinical diagnostic and biopharma services for the detection and monitoring of myelo- and lymphoproliferative disorders. The LabPMM network performs globally standardized flow cytometry and molecular testing services for pharmaceutical and healthcare organizations, providing results that are critically important for patient care in the U.S., Europe, and Asia. Join us in our mission to revolutionize oncology diagnostics and improve patient outcomes worldwide. Visit our website to discover how Invivoscribe’s ecosystem is driving advancements in precision medicine.

Ionpath delivers high definition spatial proteomics, revolutionizing tissue imaging and analysis to accelerate discovery and improve human health. Ionpath’s MIBI™ (multiplexed ion beam imaging) Platform breaks through the limitations of traditional IHC, enabling deep understanding of the tissue microenvironment with highly multiplexed quantitative single-cell analysis. With MIBI technology and the expertise of world class pathology and data science teams, Ionpath provides actionable insights to translational and clinical researchers at leading pharma, biotech, and research organizations in immuno-oncology, immunology, neuroscience and infectious disease research.

JAJ International, Inc is a worldwide leading company in the rapid one-step diagnostic industry. Founded in 1998, our scientists have developed extraordinary lines of products, many of which hold unique patents. JAJ International develops, manufactures, and markets a wide array of one-step diagnostic test kit, including Cardio markers, Infectious diseases, Drug abuse, Sexually transmitted diseases, Pregnancy and Fertility etc. Pioneered in technological breakthroughs, JAJ is the first, and in many cases the only, company who can achieve rapid tests of equal or better quality than the equivalence in Elisa tests. After many years of Research and Development and many technological breakthroughs, JAJ International is poised to take a leadership position in the Rapid Diagnostic Market.

Karius sees a world where infectious disease is no longer a major threat to human health. The Karius Test uses genomics and AI to map a patient’s microbial landscape from a single blood sample to enable clinicians to make rapid treatment decisions.

K.C. Pharmaceuticals, Inc. is committed in meeting the requirements of the Current Good Manufacturing Practices (CGMP) laid out in the Code of Federal Regulations (CFR) issued by the US Food and Drug Administration (FDA). We are devoted in producing finished pharmaceuticals and medical devices that uphold high quality standards in today's consumer market. As part of our ongoing efforts in maintaining compliance, we have been keen in implementing many systems and procedures designed to improve product quality and ensure customer satisfaction. Since our manufacturing paradigm is "Building Quality Into Products," we have various internal quality control and quality assurance checkpoints through audits, inspections, reviews, and tests to guarantee that all quality requirements have been met.

KDx Diagnostics Inc. pioneers the revolutionary URO17®bladder cancer test, poised to redefine non-invasive detection. As the co-inventor and exclusive licensee of this groundbreaking technology, KDx Diagnostics Inc. has garnered FDA Breakthrough Device Designation, CE-IVD certification, and MHRA approvals for the URO17® test. With extensive testing on thousands of samples and validation through respected peer-reviewed journals, URO17® demonstrates improved sensitivity and specificity as compared to other diagnostic tests and procedures. The URO17® urine test presents a compelling alternative to invasive diagnostics and costly imaging techniques for routine monitoring in the US, while diagnosis and monitoring for outside USA of bladder cancer, potentially setting a new gold standard in bladder cancer diagnosis and monitoring.

Kryptos Biotechnologies is a Life Science startup based in the San Francisco Bay Area. The company uses light to generate heat and control temperature, and provides innovative life science systems that reveal the complexity of biology for clinicians and scientists.

Kurin® is a privately held, certified minority owned business dedicated to engineering better healthcare through innovative, cost-effective, clinician-approved technologies. Building on the successful invention, clinical adoption, and corporate acquisition of Curos™ disinfecting port protectors, Kurin is focusing its depth of experience in medical device engineering, marketing, sales and service, to tackle the persistent and costly fallout of false positive blood cultures. With agile development capabilities and intense customer focus, we have seen the Kurin Lock® with Flash Technology quickly gain caregiver acceptance, sideline skin contaminants during blood culture collection, and become the blood culture collection standard of care in hospitals. Curos™ is a registered trademark of 3M Corporation.

Kwokman Diagnostics was founded and developed to help the fast paced sports broadcast industry return to work through accurate and quick results COVID19 testing. Through the initial journey and scope, we realized that a variety of companies would benefit from rapid turnaround results. Therefore we partnered with a number of labs, healthcare workers and logistics companies to ensure an end to end solution for any industry.

Lab Genomics, LLC (LG) is focused on delivering individualized medical care through molecular and genetic diagnostics.

Laguna Diagnostics, LLC, develops proprietary blood-based, molecular biomarker diagnostic tests for accurate diagnosis of mental disorders and neurodegenerative diseases.

Life-saving therapies. Critical diagnostics. Breakthrough clinical trials. Life Couriers places hope in the hands of patients everywhere by being the world's most trusted logistics partner for crucial pharmaceutical and medical products. We are the worldwide market leader for radiopharmaceutical and stem cell logistics. We have taken this experience with the most time-critical shipments in the world to expand our services to biopharmaceuticals, cell and gene therapies, lab specimens, clinical trials, organ transplant, medical devices, and more. We understand a fundamental reality - that missing a delivery can mean losing a life. That is why we have intentionally curated our culture to be solely focused on patient outcomes. Our people care more and they are deeply committed to enhancing, enriching, and saving lives through the power of logistics. We are Life Couriers. Logistics for Life.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its proprietary cell-based therapy platform and associated development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally-differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical assets include (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase I/IIa development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase I/IIa development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in Phase I development for the treatment of non-small cell lung cancer. For more information, please visit www.lineagecell.com.

Lumos Diagnostics, a California-based Full Service point-of-care diagnostic development company and previous spinoff from Australia-based Planet Innovation, and RPS Diagnostics, a Florida-based commercial diagnostic developer, manufacturer, and marketer of POC diagnostic tests, announced today that they have merged. The combined company will be called Lumos Diagnostics.

Machaon Diagnostics is a clinical reference laboratory and contract research organization (CRO), specializing in the diagnosis, treatment and monitoring of hemostatic and thrombotic conditions, complement-mediated disorders and rare genetic diseases. Machaon Diagnostics has a mission to save more lives with lab tests. Started as a collaboration of four laboratory scientists, we have rapidly grown into a dedicated group of clinicians, scientists, consultants and technologists. Collectively, the Machaon Diagnostics team brings over 400+ years of expertise to the field of laboratory testing. Our esoteric and routine testing menu applies to a wide variety of disorders and clinical trials and therefore draws attention from both a national and an international clientele. Our clients include community hospitals, university medical centers, clinics, commercial laboratories and research laboratories, as well as biotechnology, pharmaceutical and medical device companies. Machaon brings custom solutions to hospitals, laboratories and trial sponsors. Our primary goal is to provide quality testing (CAP/CLIA, GLP, GCP) at industry-leading speed.

Magnetic Insight is developing solutions in Magnetic Particle Imaging (MPI), a new imaging modality that directly detects iron oxide nanoparticle tracers using time-varying magnetic fields. Because the tracer is not normally found in the body, MPI images have exceptional contrast and high sensitivity.

Mammogen is a liquid biopsy company on a mission to unlock the quality-of-life preservation that exists at the earliest stages of diseases that affect women's health, starting with breast cancer.

Mammoth Biosciences is a biotechnology company focused on leveraging its proprietary ultracompact CRISPR systems to develop long-term curative therapies, as well as other applications such as decentralized precision diagnostics. Founded by CRISPR pioneer and Nobel laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington, the company’s ultracompact proteins are designed to enable in vivo gene editing in difficult to reach tissues utilizing both nuclease applications and new editing modalities beyond double stranded breaks, including base editing, gene writing, and epigenetic editing. The company is building out its pipeline of potential in vivo gene editing therapeutics and capabilities and has partnerships with leading pharmaceutical and biotechnology companies to broaden the reach of its innovative and proprietary technology. Mammoth’s deep science and industry experience, along with a robust and differentiated intellectual property portfolio, have enabled the company to further its mission to transform the lives of patients and deliver on the full promise of CRISPR technologies.

Mdxhealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California.

Meditrina is an innovative start up Company located in San Jose, CA, and founded in 2016 developed the Aveta™ hysteroscopy suite which was designed to provide physicians with the best care in their diagnosis and treatment of endometrial polyps and uterine fibroids. The system seamlessly integrates into any operating, procedure, or exam room. This new hysteroscopy system is an all-in-one platform which includes the single-use Aveta™ Pearl Hysteroscope for myomectomy, and the single-use Aveta™ Coral Hysteroscope for polypectomy procedures with integrated tissue resection and fluid management capability. The Aveta™ Pearl Hysteroscope is the first single-use hysteroscope to include full physician control providing proprietary fluid management and video control function directly on the hysteroscope handle.

Melio is developing a clinically actionable fast and comprehensive test for all common infections

mFluiDx is a UC Berkeley spinout startup that develops innovative technology to enable rapid, low-cost molecular DNA/RNA diagnostics at point-of-care.

MiCareo believes in a future where medicine can offer the right treatment for the right patient at the right time. To get us to that future, we must find crucial information that is hidden away deep inside rare cells that circulate in our body. Our mission is to unlock the secrets of these rare cells and offer a way forward for research and drug development in the pursuit of precision medicine. We invite you to join us towards these goals. We strive to deliver solutions for the fundamental unmet needs in rare cell processing for personalized medicine, clinical diagnostics, drug development, and biomarker discovery. Our proven robust technology is founded on research started in 2005. We integrated disposable microfluidics with a fully automated sample processing, laser sorting, and fluorescence imaging system, to provide the simplest tools to answer your complex rare cell questions. We provide innovative tools for the analysis of rare cells for Liquid Biopsy, Circulating Tumors Cells, Immune Cells, and Other Rare Cells. Our circulating tumor cell platform does rare cell isolation and analysis for cancer prognosis and treatment development and efficacy evaluation. We have Collaboration Service Centers in Taiwan and Seattle WA, USA, where we can process your samples and give a detailed introduction to our products and services. We also work with distributors throughout the world to offer our products globally. Contact us to get started with your rare cell analysis.

Milagen is a privately held, late-stage, pre-commercial diagnostic company focused on commercializing easy-to-use, non-invasive, in vitro diagnostic (IVD) products designed to fulfill unmet clinical needs in the prevention, detection, diagnosis, and management of major cancers. We are making the transition to commercialize our novel, proprietary antibody-based blood serum assays for detection of Breast and Colon cancer recurrence in a CLIA setting while we are preparing for a major clinical study to support an intended use for the early detection of major cancers.

Mindera Health™ is commercializing scalable extraction technology and data analysis to report a patient’s individual transcriptomic data. Mindera’s technology creates Dermal Intelligence™, actionable information for payers, providers and patients. The company’s flagship test, Mind.Px, uses both a dermal biomarker patch and Machine Learning to determine a patient’s receptivity to very expensive psoriasis biologics. This information is valuable to payers, who can save thousands of dollars per biologic patient using Mind.Px at the outset of prescription. Mind.Px is the first test in a large planned product pipeline, including psoriatic arthritis and eczema biologic receptivity.

MiraDX was founded by Joanne Weidhaas, M.D., Ph.D. and Frank Slack, Ph.D., whose cutting-edge genetic research has unveiled a new class of genetic biomarkers, based on microRNA biology. Our mission is to apply these novel biomarkers to improve personalized cancer treatment. We have been applying these biomarkers to better direct cancer treatments, including radiation, chemotherapy, and newly developing immune therapies. We are able to apply our biomarkers to the daunting problem of toxicity from treatment, which no other set of biomarkers has been able to do. Through worldwide collaborations MiraDX has advanced this class of biomarkers to the forefront of personalized therapy, and has numerous collaborations across both academic and industry. We encourage you to learn more by visiting our website at MiraDX.com, as well as through visiting our sister non-profit, MiraKind, at MiraKind.org.

Mitera is a maternal-fetal medicine (MFM) telehealth company. We help inform and educate our patients about their pregnancy-related risks and options through obstetrical screenings and at-home genetic testing kits, empowering them along their family-forming journey.

We are a tech-centered, animal diagnostics company on a mission to help veterinarians lengthen the lives of their patients by applying deep learning to the diagnostics they use daily.

Monogram Biosciences, a LabCorp company, is a leader in developing and commercializing innovative products to help guide and improve the treatment of infectious diseases, cancer and other serious diseases. Our molecular diagnostics and testing services enable Healthcare providers to optimize treatment regimens for their patients to lead to better outcomes and reduced costs by matching the underlying molecular elements of an individual patient's disease to the drug best able to affect those elements. Further, we work with pharmaceutical companies to develop new and improved antiviral therapeutics and vaccines as well as targeted cancer therapeutics more efficiently by providing enhanced patient selection and monitoring capabilities throughout the development process. We have developed HIV tests, or assays, to help make the complexities of antiretroviral therapy easier to manage. We have also developed oncology products to help accelerate the development of targeted cancer therapeutics.

More Diagnostics controls are stable, convenient, reliable, thus ensuring accurate results in your lab. We are a trusted business partner providing exceptional support in the industry and understanding of the clinical diagnostic laboratory division.

At MyOme, we help families understand their DNA, and how it impacts their health throughout their lives, with secure and portable data using the latest technologies. We are always interested to hear from smart, passionate people with a background in bio stats, data science, and ML. Connect with us!

NantHealth, a member of the NantWorks ecosystem of companies, provides enterprise solutions that help businesses transform complex data into actionable insights. By offering efficient ways to move, interpret, and visualize complex and highly sensitive information, we enable customers in healthcare, life sciences, logistics, telecommunications and other industries to automate, understand and act on data while keeping it secure and scalable. Our product portfolio comprises the latest technology in payer-provider collaboration platforms for real-time coverage decision support, and data solutions that provide multi-data analysis, reporting and professional services offerings.

NantOmics employs a comprehensive, integrated panomic approach to detect molecular alterations in individual tumors and inform personalized treatment options for patients with cancer. Whole genome sequencing of a patient’s matched tumor sample and normal sample pinpoints tumor-specific alterations at the DNA level, RNA sequencing confirms and gives relevance to mutations in DNA, quantitative proteomics measures the levels of clinically important proteins, and integrative analysis identifies disrupted pathways that are specific to the patient’s tumor.

Natera™ is a global leader in cell-free DNA (cfDNA) testing, dedicated to oncology, women's health, and organ health. Our aim is to make personalized genetic testing and diagnostics part of the standard of care to protect health and enable earlier and more targeted interventions that lead to longer, healthier lives. Where some set out to build a test, we set out to achieve a mission: change the management of disease worldwide by using DNA testing to proactively inform treatment.  Through a cfDNA technology platform approach, we've pioneered noninvasive testing in unlimited applications—each with their own potential to revolutionize care for patients. #TeamNatera includes clinicians, scientists, biostatisticians, researchers, and laboratory professionals from around the world. Our diverse teams blend a passion for patients with deep clinical, scientific, and technological roots. Natera's tests are validated by more than 100 peer-reviewed publications that demonstrate high accuracy. Interested in joining us on our mission to change the management of disease worldwide? Visit https://www.natera.com/careers-at-natera to learn how you can become a part of our talented team. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. Please be advised that Natera will reach out to candidates with an @natera.com email domain ONLY. Email communications from all other domain names are not from Natera or its employees and are fraudulent. Natera does not request interviews via text messages and does not ask for personal information until a candidate has engaged with the company and has spoken to a recruiter and the hiring team. Natera takes cyber crimes seriously, and will collaborate with law enforcement authorities to prosecute any related cyber crimes. https://www.natera.com/privacy/

NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company’s Advanced Diagnostics Division serves pharmaceutical clients in clinical trials and drug development. NeoGenomics is committed to connecting patients with life altering therapies and trials. We believe that, together, with our partners, we can help patients with cancer today and the next person diagnosed tomorrow. In carrying out these commitments, NeoGenomics adheres to relevant data protection laws, provides transparency and choice to patients regarding the handling and use of their data through our Notice of Privacy Practices, and has invested in leading technologies to secure the data we maintain. Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories for full-service sample processing in Fort Myers, Florida; Aliso Viejo and San Diego, California; Research Triangle Park, North Carolina; and Houston, Texas; and a CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom. NeoGenomics also has several, small, non-processing laboratory locations across the United States for providing analysis services. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and a pharmaceutical firm in Europe.

Newomics is a biotech company that sells and develops innovative and integrative platforms for LC-MS. In particular, the award-winning multinozzle M3 emitter, with the MnESI ion source, enhances the ionization efficiency to achieve unprecedented sensitivity, throughput, and robustness. Our proprietary technology is based on silicon-microfluidic-chip for liquid chromatography-mass spectrometry (LC-MS), and offers unprecedented robustness, sensitivity, specificity, and throughput for analyzing molecules from minute amounts of biospecimens such as blood and urine. Our core technologies are built upon the multinozzle emitter array (MEA) technology, invented from the Lawrence Berkeley National Laboratory (Berkeley Lab), which has won the 2012 R&D 100 award.

At NextGen Jane, we believe in enriching your Quality of Life, expanding your Agency, and enabling your Pursuit of Data. All good revolutions are anchored in coherent philosophies championed by an impassioned base. This is our revolution, to empower women with the information needed to make smart decisions and take true health ownership. Armed with our SmartTampon platform that serves as a sentinel system for your reproductive health, we hope to impact how you manage your health, from menarche to post-menopause. If you dig it, join us. It is hard to create new ways of engaging with our health in rigid systems within a complex care system, but not impossible. Help us re-engineer our future, in our image.

Nexus Dx is a global provider of Near Patient Testing systems and advanced diagnostic solutions. The company is improving patient care by providing the medical community with rapid and reliable information at the point of care (POC), delivering patient information when and where it is needed most. Company Highlights: Primary focus on expansion of assay systems in the Near Patient Testing industry Multi-product revenue generating business Proprietary technologies and content Highly experienced management team Nexus Dx Inc.

Nielsen BioSciences, Inc. is a private, San Diego-based biotechnology company focused on offering medical professionals trusted and valued biological products with wide-ranging applications of cell-mediated immune responses. We are building on a solid foundation of over 40 years developing and delivering antigen-based products. Our research and development leverages heterogeneous antigenic profiles to enlist cell-mediated immunity in the evaluation, treatment, or prevention of diseases. Antigenic diversity enables us to effectively address conditions missed by narrowly targeted strategies

Notable is a clinical-stage platform therapeutic company developing a new class of precision medicines: predictive precision medicines. Notable aims to be the leader in predictive precision medicine and revolutionize the way in which patients seek and receive treatment: patient population by patient population, and cancer by cancer. By transforming historical standards of care, Notable expects to provide dramatic impact for patients and the healthcare community. Notable's proprietary Predictive Precision Medicines Platform replicates ex vivo the clinical response of patients to cancer treatments with high fidelity, through its optimized integration of biological assay conditions, dynamic signal analysis, and AI-driven in-silico translation into predictive algorithms. Using its high-fidelity platform, Notable can identify and select clinically responsive patients prior to their treatment and fast-track clinical development in this patient population. Notable has created a targeted, triple de-risked in-licensing strategy and a fast-track clinical development approach that delivers a product's medical impact and commercial value faster, higher, and more likely than traditional drug development.

NovaBay Pharmaceuticals, Inc. (NYSE: NBY) develops and sells scientifically created and clinically proven eyecare and wound care products. Manufactured in the U.S., Avenova Antimicrobial Lid & Lash Solution is formulated with NovaBay's patented, proprietary, stable and pure form of hypochlorous acid. NovaBay also manufactures and sells effective, yet gentle and non-irritating wound care products. The PhaseOne® brand is distributed through commercial partners in the U.S. for professional use only, and the NeutroPhase® brand is distributed in China by China Pioneer Pharma Holdings, Limited. NovaBay's leading product Avenova® Antimicrobial Lid & Lash Solution is often prescribed by eyecare professionals for blepharitis and dry-eye disease and is available directly to consumers through online distribution channels such as Amazon.com. It is clinically proven to kill a broad spectrum of bacteria to help relieve the symptoms of bacterial dry eye, yet is non-irritating and completely safe for regular use. NovaBay offers a full portfolio of scientifically developed products for each step of the standard dry eye treatment regimen, including the Avenova Eye Health Support antioxidant-rich oral supplement, Avenova Lubricating Eye Drops for instant relief, Avenova Warm Eye Compress to soothe the eyes and the i-Chek by Avenova to monitor physical eyelid health. The Avenova Allograft, an amniotic tissue prescription-only product, is available through eyecare professionals in the United States. For more information, please visit www.novabay.com.

Novodiax is a biotech startup dedicated to advancing cancer and autoimmunity diagnostics through innovative rapid immunoassays. Our revolutionary ihcDirect® assays are listed for in vitro diagnostic (IVD) use and provide immunohistochemistry (IHC) results in as little as 10 minutes on frozen tissues! They also provide workflow benefits for formalin-fixed, paraffin-embedded (FFPE) tissues, helping reduce assay time by up to 40-60 minutes. ihcDirect works by directly conjugating primary antibodies to our proprietary and sensitive polymerized horseradish peroxidase (polyHRP) detection system, thus delivering immunoassays for histology and cytology (2020) that: - Are lightning fast (~10 minutes) - Require minimal lab space and no specialized equipment - Can be performed at room temperature - Are simple to perform like H&E tests, yet provide the sensitivity and specificity of immunoassays Our assays are also perfect for helping you advance your research (see our ihcPrime™ and Q-Stain® products and custom services), develop cutting edge companion diagnostics (CDx), and more. Let's partner together to make that happen! Visit our website or contact us to learn more. www.novodiax.com sales@novodiax.com

Sample prep engineered for liquid biopsy. nRichDX, based in Irvine, CA is an emerging leader in the liquid biopsy sample prep market, delivering significantly more analyte (cfDNA, ctDNA, cfTNA, cfRNA) than existing sample prep systems for molecular testing. The nRichDX liquid biopsy sample prep platform is the result of an intensive technology development effort that commenced in 2016. Being introduced in late 2018, the nRichDX system is a 510K-exempt, highly differentiated, universal sample prep system for the multi-billion dollar liquid biopsy and precision medicine markets. nRichDX solves one of precision medicine’s greatest problems - - inaccurate diagnostic results for up to 50% of liquid biopsy-based molecular diagnostic tests (NGS, PCR, Micro Array, etc.) due to a lack of target material. The nRichDX platform improves workflow, greatly enhances test sensitivity and produces consistently reliable test results while increasing revenue and reducing operational costs and complexity.

OKRA Care is highly committed to providing hospital-grade glucose monitoring test kits to help patients manage diabetes effectively

Onc.AI is venture-capital backed company committed to developing robust, clinically validated, imaging-AI powered clinical management solutions focused on immunotherapy optimization. Using patented, radiomic-based AI models, Onc.AI has developed a clinical decision support platform using routine diagnostic imaging scans specifically for planning and guidance of first-line immune checkpoint inhibitors (ICI) treatment plans.

Oncobox is transforming cancer care with precision medicine by leveraging the power of artificial intelligence and systems biology. Through the integration of deep molecular profiling—which includes analysis of not only DNA mutations (exome) but also RNA gene expression (transcriptome)—and comprehensive data analytics, we achieve unmatched precision in identifying the most effective treatment strategies, markedly improving outcomes for patients battling late-stage cancers. The effectiveness of Oncobox's technology is backed by both prospective and retrospective studies. This approach has shown remarkable success, leading to a twofold decrease in disease progression and a significant increase in progression-free survival (PFS). Oncobox's innovative use of deep molecular profiling is setting new standards in the precision and efficacy of cancer treatment.

Oncocyte is a precision diagnostics company with a mission to improve patient outcomes by providing personalized insights that inform critical decisions. They are focused on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer.

OnsiteGene Inc. is a biomedical technology company developing on-site genetic testing based on a new sample prep and qPCR process.

As a global leader in digital pathology, OptraSCAN is dedicated to revolutionizing diagnostics and patient care through advanced technology. We specialize in providing cutting-edge digital pathology solutions, including state-of-the-art digital pathology scanners and whole slide imaging scanners, designed to enhance the accuracy and efficiency of diagnostic processes. Our extensive range of digital slide scanners includes brightfield slide scanners, histology slide scanners, and fluorescence slide scanners, enabling healthcare institutions to transition seamlessly from traditional microscopy to sophisticated digital pathology systems. Our whole slide scanners and digital pathology slide scanners offer high-resolution imaging that improves precision, streamlines workflows, and provides cost-effective results. OptraSCAN leads the way in digital histopathology with innovative solutions that integrate advanced artificial intelligence (AI). Our AI-powered pathology scanners and digital pathology artificial intelligence technologies are designed to boost diagnostic accuracy and efficiency. We offer comprehensive solutions including whole slide imaging scanners and computer-aided region detection systems. We are committed to making digital pathology accessible to all, providing compact and advanced scanning systems that overcome barriers to modern diagnostic methods. Our digital pathology solutions include cloud-based LIMS (CLOUDPath), image analysis tools (OptraASSAYS), and up to 10 TB of complimentary cloud storage. By choosing OptraSCAN, you partner with a leading digital pathology company that is shaping the future of diagnostics with high-quality digital pathology scanners and integrated whole slide imaging solutions. Our goal is to ensure that healthcare systems worldwide can seamlessly adopt and benefit from our transformative digital pathology technologies.

Pattern Ag uses predictive analytics to help farmers with input decisions such as crop protection, seed selection, and fertility needs. Pattern envisions a future where conventional agricultural inputs are enhanced and eventually replaced by precision microbiome engineering, improving farm productivity and sustainability.

Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics. The company also provides a complementary liquid biopsy assay that analyzes various human genes versus. It serves biopharmaceutical customers, universities and non-profits, diagnostics companies, and government entities. The company has partnership with Berry Genomics; Natera, Inc.; and MapKure, LLC. Personalis, Inc. was founded in 2011 and is headquartered in Menlo Park, California.

Disrupting research enzyme/protein production, we are the first to introduce a Taq Polymerase free from background DNA contamination. We are now proud to introduce our new RNA extraction free EF1 SARS-CoV-2 Detection Kit, CE marked for in vitro diagnostics! Find out how we plan to have the gold standard of testing available with results in less time it takes to explain your job to grandma!

PHASE Scientific is a high-growth biotech company with a mission to inspire a new state of health. Headquartered in Hong Kong with locations in Southern California and China's Greater Bay Area, we provide novel diagnostic tools and services for cancer and infectious diseases with our proprietary technologies. REVOLUTIONIZING HEALTHCARE THROUGH BETTER INSIGHT Better treatment starts with more timely and more precise detection, at the very beginning. Our proprietary technology, PHASIFY™, redefines the gold standard of diagnostics by making target molecules quicker and easier to detect. The technology, with the ability to concentrate target molecules by 10-100x, can help track down hidden conditions that are otherwise neglected, making diagnostics test more affordable, accessible, faster, easier, and more accurate. PHASIFY™ has a huge potential to be used in a wide range of applications. We are committed to further strengthening the research and development efforts to develop best-in-class screening and diagnostic tools and services in cancer and infectious diseases. Our aspiration is to support people in every step of their integrated healthcare journey, from early screening, diagnostics, treatment to ongoing monitoring, so as to make everyone healthier. PRODUCTS AND SERVICES INDICAID™ | At-home rapid tests that can be used anytime, anywhere PHASE lab | Medical lab for cancer and infectious diseases, powered by PHASIFY™

PinkDx is an early-stage company whose vision is to positively impact the health of women throughout their life journey. We focus on addressing the medical problems that women uniquely face by applying sophisticated scientific approaches to resolve them and provide answers that have an immediate, positive impact on their lives. Our first indication will focus on overcoming diagnostic challenges for women who present with general symptoms that could signal a gynecological cancer. Led by a team of diagnostics industry veterans, PinkDx is privately held, with funding from prominent biotechnology investors, including Catalio Capital Management, The Production Board, Mountain Group Partners, Byers Capital and Mayo Clinic.

Predicine is a global molecular insights company that is committed to advancing precision medicine in oncology. Predicine has developed a breakthrough cell-free DNA- and cell-free RNA-based liquid biopsy technology enabling minimally invasive molecular diagnosis for treatment selection, therapy monitoring, and minimal residual disease and early cancer detection. The company has launched a portfolio of blood-, urine- and tissue-based diagnostic assays for oncology. Through its business operations in Silicon Valley, Houston, Shanghai, Singapore, and Boston, Predicine partners with leading biopharma companies, institutions and governments to support personalized healthcare on a global scale.

At Primex Clinical Laboratories, we're dedicated to enhancing health with precision and passion. Since 1996, our presence in clinical diagnostics has been unwavering, serving diverse clients across Central and Southern California, Nevada, and American Samoa. We're more than a testing facility, our laboratory is a center of innovation and reliability. We pride ourselves on delivering personalized customer service, and high-quality testing with quick and accurate results, contributing to our community's health and well-being. Understanding the vital role of diagnostics in healthcare, we aim to be your most trusted lab partner. Our focus extends beyond recognition; we strive to gain your trust through personalized service, precise testing, and innovative solutions. We dedicate ourselves daily to advancing healthcare with meticulous care and a personal touch, shaping a healthier future. Learn more at Primexlab.com.

Harnessing the Power of Cytokine Monitoring and Host-Response Understanding to Transform Healthcare Cytokines, pivotal biomarkers of inflammation, are essential in tracking the progression of infections, helping physicians tailor more effective treatments. Annually, over 10 million patients in the U.S. are diagnosed with infections, and the post-COVID-19 era has highlighted the value of cytokine monitoring. However, the current methodologies are costly and slow, undermining its potential. Our solution introduces point-of-care cytokine testing that matches central lab accuracy, completed in just 5-10 minutes, and at a significantly lower cost. This enables continuous, real-time monitoring, offering timely, actionable insights to both physicians and patients exactly when needed. Proactive Diagnostics is transforming how infections are assessed and managed, to improve care in several critical areas: - Enhancing clinical outcomes - Minimizing unnecessary antibiotic use - Shortening hospital stays - Reducing patient readmissions Our AI-driven, cloud-connected platform leverages unique data collection capabilities to deepen our understanding of individual host responses to various inflammatory stimuli. Such capabilities can also play a critical role in other important clinical areas such as the treatment of Autoimmune Diseases, where monitoring host response can inform therapy adjustments and drastically improve lives; or in the treatment of Cancer, where Cytokine levels can help optimize the administration of groundbreaking immunotherapies and adjust treatments to harness the immune system's power more effectively against tumor cells. This transformation in cytokine monitoring could be the key to a new era of personalized, predictive, and preventative medicine, where each patient's treatment is as unique as their response to disease.

ProciseDx is helping patients leave appointments with answers instead of just another appointment. Our point-of-care diagnostic solutions are enabling faster decisions for patients and physicians.

PrognomiQ aims to generate proteomic information with high accuracy, scale and speed. This proteomic data will be complemented with genomic, metabolomic and other health information to deliver first-in-class test products that enable early disease detection and treatment. Powerful, Untapped Disease Insights Built on a Proteomics Foundation: Until now, there have been major technical and economic barriers to broad-scale proteomics analyses, leaving this rich resource of molecular information largely untapped for clinical purposes. These barriers have now been largely addressed through next generation tools that can elucidate complex proteomics at scale. Complementary Molecular Information: Genomic data has made clear contributions to researchers' abilities to understand and more precisely treat disease, but it is has shown limited impact on early-stage disease detection. Proteomics provides direct information on the biological state of a cell, including disease at its earliest state, but proteomics data has been technically difficult to generate – until now. By complementing the new sources of proteomics data with genomics and other data, such as metabolomics, we now have the tools to generate powerful multi-omics data that will be the key to unlock the detection and treatment of disease at its earliest stages, when these diseases are most likely to be cured. Unlocking Disease Detection and Treatment with Multi-omics Data: We designed our proprietary multi-omics platform around the most robust approaches to generating proteomic, genomic and metabolomics data at scale, including the use of the Proteograph technology platform from the life science tools company Seer (NASDAQ: SEER) whom PrognomiQ spun out of in 2020.

Promaxo is a medical technology company that develops and commercializes customer-centric MRI systems and MRI based technologies that enhance patients' experiences and outcomes. The Promaxo MRI system is designed for image-guided interventions including live MRI guided biopsies, treatment planning, robotic surgeries, and radiation.

Proxim Diagnostics - Next-generation point-of-care solution. COVID-19 antigen test.

The QTI team has been on an incredible journey, starting with a shared mission to create disruptive innovation to expand access to medical imaging while ensuring superior patient experience and improving health outcomes. We anchor our efforts in medical imaging because when the body can be scanned often and without harm, health conditions can be detected before symptoms appear. Chief among the new advancements in medical imaging is 3D body imaging. Today QTI focuses on our breast imaging technology, which is native 3D, high resolution, and generates reproducible image quality regardless of operator or breast size or tissue type. Current breast imaging paradigm leads to unnecessary concern and cost. ▪️Unlike mammography, QTI technology is effective in screening women with dense breasts, or 40% of women in US. ▪️35% of women aged 40-70 do not get screened. Of the 65% of women who get screened, 15% suffer unnecessary callbacks for ultrasounds, MRI, or biopsies. 80% of biopsies are benign. ▪️QTI’s technology can be a much-needed alternative for high risk women under 40, as cancers in younger women are usually aggressive and survival outcomes are poor. Our QT Imaging Breast Acoustic CT™ Scanner is the only true 3D imaging device, FDA cleared for use as a transmission and reflection low frequency soundwaves imaging system for a patient’s breast. There is no ionizing radiation or compression like in mammography or contrast dyes injections like in MRIs. The technology uniquely quantifies breast density. Surface-to-volume ratios and volumetric doubling time growth rate can be calculated to determine significance of lesions and improve specificity. This breast scanning system gives women the choice they deserve to ensure their breast health over time; for healthcare providers, a technology that is accessible, affordable, and accurately visualizes internal structures of the breast; and, for investors, a market segment extension and a purposeful investment opportunity.

QuidelOrtho develops and manufactures intelligent solutions that are transforming data into understanding and action for more people in more places every day, helping spot trends sooner, respond quicker and chart the course ahead with accuracy and confidence. Together, we are advancing diagnostics to power a healthier future.

QuidelOrtho develops and manufactures intelligent solutions that are transforming data into understanding and action for more people in more places every day, helping spot trends sooner, respond quicker and chart the course ahead with accuracy and confidence. Together, we are advancing diagnostics to power a healthier future.

Ravata Solutions is a fertility and reproduction company that specializes in hardware and diagnostics to transform the IVF laboratory with automated assisted reproductive technologies (AART) and enhance human disease model development for pre-clinical studies.

The CLIA-certified Razor Genomics Molecular Prognostic Assay is helping with precision management of the world’s deadliest cancer

Real Time Genomics develops analytical solutions that reduce the cost and complexity of extracting knowledge from raw genomic data. We deliver validated, accurate results that are redefining personalized medicine. ___________________________________________________________________________________ At Real Time Genomics, we have a passion for genomics. Our core competence is a commitment to know, anticipate and deliver to the needs of leading biological researchers. The company has deep computational expertise in algorithms, coupled with extensive product development capabilities and a seasoned commercial team with over 100 years of success in bringing genomics' innovation to the life sciences industry. Today,we offer solutions for genomic analysis to practitioners of next generation sequencing (NGS) technologies. These solutions include complete analytical platforms for genomics and metagenomics. We can install these platforms to your compute environment or provide you access to them through cloud computing.

The company uses biology-guided radiotherapy to detect and respond to signals emitted from cancer cells, and use them to guide treatment.

We develop immunologic therapeutics and diagnostics designed to make the world a healthier place. $6.2 Million Public Offering on February 5, 2024.

Salimetrics supports thousands of salivary researchers in more than 20 countries around the world. Our assays have been used in more saliva-related published papers than any other assay in the field. We believe Salimetrics is a unique company. We combine uncompromising scientific process with human passion to deliver what we hope are superior products and services for saliva testing and collection. We provide consultation, assistance with study design, advice for funding, and support for all things saliva testing-related, because we believe saliva testing can help researchers learn and discover things that will translate to cures, treatments and understanding around the world. If you have a ground-breaking study, ideas for innovative saliva testing products, or simply need advice, please don't hesitate to contact us. We work with a diverse network of saliva researchers around the world. This network extends the salivary research community by providing credible, data driven results that advance the scientific field of salivary research. Together, we can make a difference. To place an order, request a quote, or have your questions answered please visit our website. https://salimetrics.com/contact/ We are always ready to assist you!

In vitro diagnostic company, specializing in the production of antibodies, controls, blockers including HBR. - Clean Rooms - Filling - Finishing - Packaging - Sub-Assembly - Inventory Space - Kit Manufacturing - Lyophilization - Antibody Production - Medical Device Manufacturing

Serimmune is an immune intelligence company that provides a holistic view of immunity to identify environmental factors in disease and health. Serimmune’s Serum Epitope Repertoire Analysis (SERA) technology platform applies bacterial display peptide libraries, next generation sequencing, machine learning and custom bioinformatics to reveal the many diverse antigens stimulating immunity.

Siemens Healthineersenables healthcare providers worldwide to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving patient experience and digitalizing healthcare.COVID-19: CE mark for its molecular Fast Track Diagnostics (FTD)SARS-CoV-2 Assay.

Silver Lake Research Corporation is a biotechnology company based in Monrovia, California, founded in 1992. The company specializes in the development and manufacturing of diagnostic test kits, focusing on rapid point-of-care diagnostics. Their proprietary EAP™-derived monoclonal antibodies ensure high accuracy and sensitivity, comparable to laboratory assays. The company offers a range of diagnostic test kits, including those for water quality, air contaminants, and urine analysis. Their Watersafe® line features a highly sensitive water lead test and comprehensive bacterial detection. Additionally, Silver Lake supplies bio-engineered proteins for therapeutic drugs and diagnostic components to other companies. They operate one of the largest independent automated production facilities for lateral flow tests in the U.S. Silver Lake Research emphasizes consumer safety, targeting concerns related to waterborne pathogens and carcinogens. They also provide white-label components for third-party diagnostic kits, indicating strong partnerships within the industry. The company operates from two locations, with general operations in Monrovia and administrative functions in Irwindale.

SiteOne Therapeutics is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of hypersensitivity disorders such as pain, itch, and cough. The company is advancing a novel class of highly selective small molecule inhibitors to target Nav1.7, Nav1.8, and Nav1.9 sodium ion channels. SiteOne Therapeutics is dedicated to the development of novel therapeutics to safely and effectively treat pain and other hypersensitivity disorders.

SmartHealth Dx develops precision diagnostics that address unmet clinical needs in pathology and vascular inflammation for advancing today's standard.

info@smlgenetree.com | www.smlgenetree.com | SML Genetree is recognized as a premier partner in developing technology and on-time delivery, providing both basic research of molecular biology and applied research in molecular diagnosis. SML Genetree is an affiliate of Samkwang Medical Laboratories (SML), one of the largest diagnostic commercial labs in South Korea in 1985.

SomaGenics is a privately held biotech company with offices and laboratories located in Santa Cruz, CA. We specialize in small RNA technologies, including innovative RNAi-based therapeutics using sshRNA molecules, and diagnostics/biomarker detection (NGS, quantitative PCR) of small or fragmented RNA, including microRNA.

Sorrento Therapeutics is an antibody-centric, clinical stage biopharmaceutical company developing new treatments for cancer, inflammation and autoimmune diseases. Sorrento's lead products are multiple late-stage biosimilar and biobetter antibodies, as well as clinical CAR-T therapies targeting solid tumors.

StrokeDx provides portable, rapid, and non-invasive stroke diagnostic and imaging tools.

Subtle, Inc., is a medical imaging software company. Our goal is to improve the quality, value, and accessibility of medical imaging by significantly reducing cost, imaging time, and radiation dose. We use the state-of-art proprietary deep learning AI algorithms to renovate the radiology workflow to deliver faster, safer and smarter solutions for imaging exams.

Superfluid Dx is a biotechnology company focused on developing accurate diagnostics for neuro-degenerative diseases by harnessing the power of cell-free mRNA. They are also working on novel blood-based early detection methods.

To achieve more precise care for every patient, we need to transform real-world evidence into insights that can directly impact care. At Syapse, that is real-world care. It’s found in the way we empower healthcare organizations to work together in active, transparent partnerships, delivering complete patient insights to answer the questions that matter and then purposefully applying it at where patients receive care – driving real impact for cancer patients and beyond.

Founded with a purpose to bring the full power of a lab to those providing care, Talis Bio is dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care. While timely diagnosis of infectious diseases is critically important to enable effective treatment, testing is primarily performed in centralized laboratories, which require specimens to be shipped for processing, delaying the return of results by days. Point-of-care testing solves this problem by empowering healthcare providers to generate lab quality results without the wait. From the doctor's office to remote care settings, we are re-defining the treatment of infectious diseases. The Talis One™ point-of-care system is designed to deliver fast, accurate, lab-quality molecular diagnostic testing in a variety of health care settings. Talis Bio strives to deliver results from sample to answer in less than 30 minutes. To achieve our purpose, we focus on three things: 1. Putting customers and patients first 2. Making Talis Bio a great place to work 3. Living our values to Dream Big, Share Our Screens, Serve Others, Bring Our "A" Game, and Build Trust

Target Discovery is a company that specializes in innovative testing strategies using analytical instrumentation, surface chemistry, microfluidics, nanotechnology, signal processing, and machine learning to provide affordable and accurate results.

Emerging diagnostics company.

True Diagnostics (True) designs and develops innovative POC diagnostic tests and devices based on its proprietary TrueDX™ Platform, which utilizes reliable and low-cost lab methods and its own proprietary or partnered biomarkers to offer rapid diagnoses to facilitate treatment decisions in point-of-care, point-of-incidence and remote-of-care settings. The TrueDX Platform's portability and affordability allow it to be easily adopted into emerging markets to provide accurate diagnosis within minutes. For the $21 billion point-of-care market, the power of the TrueDX Platform lies in its simplicity and flexibility. Tests have an 18-month or longer shelf life with no refrigeration required. The platform's flexible design additionally permits it to quickly commercialize a myriad of biomarkers discovered for cancer, autism, Alzheimer's, diabetes, drugs of abuse, infectious diseases, cardiac health, traumatic brain injury, viral and bacterial infections and more.

Trukera Medical is a global leader in developing and marketing comprehensive corneal health technologies. The company introduced tear osmolarity testing to eye care with its flagship device, the TearLab Osmolarity System, which has been used over 24 million times worldwide. Trukera’s expanding portfolio continues to focus on improving corneal health, both as a primary goal and in preparation for surgery. Get more details and new product announcements at www.trukera.com.

Trukera Medical is a global leader in developing and marketing comprehensive corneal health technologies. The company introduced tear osmolarity testing to eye care with its flagship device, the TearLab Osmolarity System, which has been used over 24 million times worldwide. Trukera's expanding portfolio continues to focus on improving corneal health, both as a primary goal and in preparation for surgery. Get more details and new product announcements at www.trukera.com.

Truvian is a transformational diagnostic company bringing lab-accurate results to the point-of-action where consumers engage healthcare providers to lead healthier lives. With a focus on making routine blood testing accessible, convenient, and transparent, Truvian is accelerating the transition to a sustainable healthcare ecosystem through its comprehensive benchtop solution that delivers timely, actionable results to help stop disease before it starts.

Uh-Oh Labs is a medical technology company that develops diagnostic tests through their Loop-de-Loop platform, offering simplicity, speed, and lower costs for accurate lab-grade results.

UroViu Corporation's mission is to revolutionize the cystoscopy platform for improved patient care and efficiency and has operations in California and Washington and production facilities in Asia. UroViu is the developer of the always ready cystoscopy platform, the most portable, self-contained and versatile single-use cystoscopy solution on the market. The intuitive portable platform and product suite are protected by a portfolio of 13 granted and many more pending patents. UroViu's vision is to simplify the scope of patient care.

Vascular BioSciences (VBS), a biomedical company with operations in Research Triangle, NC, San Diego, and Goleta, CA, makes interventional catheters to obtain pulmonary endoarterial biopsies, provides molecular diagnostic services, and through its majority-owned subsidiary, VBS Pharmaceuticals, advances targeted therapies in order to enhance and prolong huma

Veda is derived from the Sanskrit word for the creation of knowledge. With our team of industry leading experts, we operate at the forefront of scientific innovation to push the limits of what’s possible in the field of molecular detection. VedaBio is unlocking a universe of possibilities in molecular biology with a breakthrough platform for near-instant molecular detection of highly multiplexed analytes, delivering best-in-class accuracy without the need for target amplification.

Veracyte is a global diagnostics company that empowers clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our growing menu of diagnostic tests answers important clinical questions to help patients avoid risky, costly procedures and interventions, and accelerate time to appropriate treatment.

VitalConnect is a leader in wearable biosensor technology. Its technology is routinely used for cardiac monitoring as well as patient monitoring in the hospital and at home. VitalConnect leverages extensive expertise in biomedical engineering, data analytics, chip design, and mobile and cloud software to create technology that supports decision-making paradigms that achieve better health and economic outcomes. VitalConnect's products, the Vista Solution™ platform, and VitalPatch® biosensor are designed for use in a broad range of inpatient and outpatient settings, such as hospital monitoring, post-discharge care, cardiac monitoring and pharmaceutical solutions.

Circulating Tumor Cells (CTCs) are cancer cells, which have detached from the primary tumor and have entered the patient bloodstream. These CTCs are known to be the key cause of secondary tumors in patients. As a result, the number and type of CTCs in a patient blood is highly indicative of the status of cancer in that patient. CTCs provide insight into the source of the primary tumor, grade, invasiveness, response to therapy and recurrence. As an indication, approximately 1.5 million new cancer patients are diagnosed per year in the United States, and around 20 million existing patients are undergoing monitoring. Vortex Biosciences has a mission to be the innovation leader in CTC capture technology delivering diagnostic tests that improve therapeutic decisions and save lives. We have introduced the VTX-1 Liquid Biopsy System which automates the isolation and collection of CTCs from blood samples. Our platform has the potential to revolutionize cancer diagnosis leading to better therapeutic outcomes. Further potential applications include clinical research and the identification of cancer therapies and drug targets. To learn more about this transformative technology, please visit our website at www.vortexbiosciences.com

Wave 80 Biosciences is a healthcare technology company that develops next-generation molecular diagnostics instruments and consumables for various human health conditions with a unique one patient-one test model.

XP Health is a digital-first vision platform focused on eye exams and eyewear that uses customer-centric design and technology to be more affordable, accessible, and provide a better member experience. XP Health was founded to combat the often confusing, expensive, and frustrating experiences common with vision insurance. The company was named to Fast Company’s list of “The World's Most Innovative Companies,” and in 2022 expanded from 30 to 1500+ customers.

Zeto has developed a wireless, portable full-montage EEG headset with dry electrodes and cloud platform. Zeto's products revolutionize EEG care by offering quick setup, residue free dry electrodes for high-quality EEGs and seizure detection, 24/7 monitoring and round-the-clock remote interpretation services. Zeto is on a mission to dramatically improve EEG access, bringing to market EEG that's so easy to use in both inpatient and outpatient settings.